BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 24651962)

  • 1. Physiologically based pharmacokinetic modelling of methotrexate and 6-mercaptopurine in adults and children. Part 2: 6-mercaptopurine and its interaction with methotrexate.
    Ogungbenro K; Aarons L;
    J Pharmacokinet Pharmacodyn; 2014 Apr; 41(2):173-85. PubMed ID: 24651962
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Physiologically based pharmacokinetic modelling of methotrexate and 6-mercaptopurine in adults and children. Part 1: methotrexate.
    Ogungbenro K; Aarons L;
    J Pharmacokinet Pharmacodyn; 2014 Apr; 41(2):159-71. PubMed ID: 24651961
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The interaction of 6-mercaptopurine (6-MP) and methotrexate (MTX).
    Giverhaug T; Loennechen T; Aarbakke J
    Gen Pharmacol; 1999 Oct; 33(4):341-6. PubMed ID: 10523073
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and pharmacodynamics of oral methotrexate and mercaptopurine in children with lower risk acute lymphoblastic leukemia: a joint children's cancer group and pediatric oncology branch study.
    Balis FM; Holcenberg JS; Poplack DG; Ge J; Sather HN; Murphy RF; Ames MM; Waskerwitz MJ; Tubergen DG; Zimm S; Gilchrist GS; Bleyer WA
    Blood; 1998 Nov; 92(10):3569-77. PubMed ID: 9808549
    [TBL] [Abstract][Full Text] [Related]  

  • 5. De novo purine synthesis inhibition and antileukemic effects of mercaptopurine alone or in combination with methotrexate in vivo.
    Dervieux T; Brenner TL; Hon YY; Zhou Y; Hancock ML; Sandlund JT; Rivera GK; Ribeiro RC; Boyett JM; Pui CH; Relling MV; Evans WE
    Blood; 2002 Aug; 100(4):1240-7. PubMed ID: 12149204
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and experimental pharmacokinetic interaction between 6-mercaptopurine and methotrexate.
    Innocenti F; Danesi R; Di Paolo A; Loru B; Favre C; Nardi M; Bocci G; Nardini D; Macchia P; Del Tacca M
    Cancer Chemother Pharmacol; 1996; 37(5):409-14. PubMed ID: 8599862
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The course of biological parameters and 6-mercaptopurine pharmacokinetics during maintenance treatment of children with acute lymphoblastic leukaemia.
    Hayder S; Björk O; Lafolie P
    Acta Paediatr Scand; 1990; 79(8-9):832-7. PubMed ID: 2239280
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Importance of oral antimetabolite "maintenance" therapy in childhood lymphoblastic leukemia.
    Lilleyman JS
    Pediatr Hematol Oncol; 1996; 13(5):vii-x. PubMed ID: 10897808
    [No Abstract]   [Full Text] [Related]  

  • 9. 6-mercaptopurine dosage and pharmacokinetics influence the degree of bone marrow toxicity following high-dose methotrexate in children with acute lymphoblastic leukemia.
    Schmiegelow K; Bretton-Meyer U
    Leukemia; 2001 Jan; 15(1):74-9. PubMed ID: 11243403
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population pharmacokinetic and pharmacogenetic analysis of 6-mercaptopurine in paediatric patients with acute lymphoblastic leukaemia.
    Hawwa AF; Collier PS; Millership JS; McCarthy A; Dempsey S; Cairns C; McElnay JC
    Br J Clin Pharmacol; 2008 Dec; 66(6):826-37. PubMed ID: 18823306
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Physiologically based pharmacokinetic model for 6-mercpatopurine: exploring the role of genetic polymorphism in TPMT enzyme activity.
    Ogungbenro K; Aarons L;
    Br J Clin Pharmacol; 2015 Jul; 80(1):86-100. PubMed ID: 25614061
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of high-dose methotrexate on intracellular 6-mercaptopurine disposition during interval therapy of childhood acute lymphoblastic leukemia.
    Adam de Beaumais T; Dervieux T; Fakhoury M; Medard Y; Azougagh S; Zhang D; Yakouben K; Jacqz-Aigrain E
    Cancer Chemother Pharmacol; 2010 Sep; 66(4):653-8. PubMed ID: 20033410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of mercaptopurine: plasma drug and red cell metabolite concentrations after an oral dose.
    Welch J; Lennard L; Morton GC; Lilleyman JS
    Ther Drug Monit; 1997 Aug; 19(4):382-5. PubMed ID: 9263376
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population pharmacokinetics of high-dose methotrexate in children with acute lymphoblastic leukaemia.
    Aumente D; Buelga DS; Lukas JC; Gomez P; Torres A; García MJ
    Clin Pharmacokinet; 2006; 45(12):1227-38. PubMed ID: 17112298
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intracellular disposition of methotrexate in acute lymphoblastic leukemia in children.
    de Beaumais TA; Jacqz-Aigrain E
    Curr Drug Metab; 2012 Jul; 13(6):822-34. PubMed ID: 22571483
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison of red blood cell thiopurine metabolites in children with acute lymphoblastic leukemia who received oral mercaptopurine twice daily or once daily: a Pediatric Oncology Group study (now The Children's Oncology Group).
    Bell BA; Brockway GN; Shuster JJ; Erdmann G; Sterikoff S; Bostrom B; Camitta BM;
    Pediatr Blood Cancer; 2004 Aug; 43(2):105-9. PubMed ID: 15236274
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population pharmacokinetics of methotrexate in Mexican pediatric patients with acute lymphoblastic leukemia.
    Medellin-Garibay SE; Hernández-Villa N; Correa-González LC; Morales-Barragán MN; Valero-Rivera KP; Reséndiz-Galván JE; Ortiz-Zamudio JJ; Milán-Segovia RDC; Romano-Moreno S
    Cancer Chemother Pharmacol; 2020 Jan; 85(1):21-31. PubMed ID: 31673826
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A mathematical model of white blood cell dynamics during maintenance therapy of childhood acute lymphoblastic leukemia.
    Le TTT; Jost F; Raupach T; Zierk J; Rauh M; Suttorp M; Stanulla M; Metzler M; Sager S
    Math Med Biol; 2019 Dec; 36(4):471-488. PubMed ID: 30357334
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antagonism by methotrexate on mercaptopurine disposition in lymphoblasts during up-front treatment of acute lymphoblastic leukemia.
    Dervieux T; Hancock ML; Pui CH; Rivera GK; Sandlund JT; Ribeiro RC; Boyett J; Evans WE; Relling MV
    Clin Pharmacol Ther; 2003 Jun; 73(6):506-16. PubMed ID: 12811360
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intraindividual variation in 6-mercaptopurine pharmacokinetics during oral maintenance therapy of children with acute lymphoblastic leukaemia.
    Lafolie P; Hayder S; Björk O; Peterson C
    Eur J Clin Pharmacol; 1991; 40(6):599-601. PubMed ID: 1884741
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.